Compare Nike Inc (NKE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Tango Therapeutics Inc. — how do they compare? Nike Inc trades at $35.01 (market cap $52.48B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nike Inc is far larger — about 14× Tango Therapeutics Inc.'s market cap, and Nike Inc pays a 4.64% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Tango Therapeutics Inc. for 0 Days on average.
| NKE | TNGX | |
|---|---|---|
Market Cap | $52.48B | $3.75B |
Volume | 30,189,626 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $32.90 |
52-Week Low | $33.87 | $7.50 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $55.18B | $2.77B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $35.35, up 1.84% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from declining revenue ($46.31B in 2025 vs. $51.4B in 2024) and compressed margins (net margin 6.74%), though valuation appears reasonable with P/E of 16.9. Analyst consensus remains mixed with 47% buy ratings but a $36.80 price target suggesting limited upside. Recent news highlights inventory challenges and China market pressures.
Nike's turnaround strategy focuses on inventory discipline and digital DTC growth, but execution risks persist amid weak consumer demand. The stock offers moderate value at current levels with dividend support, though revenue stabilization is critical for sustained recovery. Near-term catalysts include Q4 2026 earnings on June 30, 2026.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
